VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DSGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksDSGNInstitutional Holders

DSGN logoDesign Therapeutics, Inc. (DSGN) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+10.84 pp), though top 10 holders maintain a highly concentrated 65.4% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
84.1%$752M total value · ▲ +10.84 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
69 / 100Bullish
Institutions & Flow137 holders+11 net flow (+27 / -16)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+11)
  • Point72 Asset Management, L.p. and Renaissance Technologies Llc maintain significant positions
  • Top 10 holders control 65.4% of institutional value
  • No Insider Signal

Top Institutional Holders of DSGN

Ranked by reported Q2 2026 13F market value

Top 10 Holders
65.4%
Top 25 Holders
89.1%

Share of total reported institutional value in DSGN held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1DUNHAM TRUST Co7.7M$111.0M0.0%12.278%51.08%
2SR ONE CAPITAL MANAGEMENT, LP6.5M$94.4M0.0%10.450%9.09%
3Logos Global Management LP3.0M$43.4M+53.8%4.803%1.87%

Quarterly Institutional Activity

Filings activity in DSGN during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers27Added To87Trimmed21Exited16
  • DUNHAM TRUST Co$111.0M
  • SR ONE CAPITAL MANAGEMENT, LP$94.4M
  • Logos Global Management LP

DSGN Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026137+8.7%84.10%+10.84 pp$752M+57%
Q1 2026126+6.8%73.26%+9.18 pp$479M+35%
Q4 2025118+24%64.08%+3.41 pp$354M+39%
Q3 202595+1.1%60.67%0.11 pp$255M+124%
Q2 2025944.1%60.78%+1.64 pp$114M9.9%
Q1 202598+4.3%

How DSGN Compares to Peers

Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
IRLAIRulya Therapeutics Inc.$39M23.9%42-29

DSGN — Frequently Asked Questions

Quick answers to the most common questions about buying DSGN stock.

What percentage of DSGN is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Design Therapeutics, Inc. stands at 84.1%, held across 137 reporting institutions.

Who is the largest institutional holder of DSGN?

DUNHAM TRUST Co is the largest reported institutional holder of DSGN, with approximately 7,668,710 shares worth $0.11B as of Q2 2026.

Is DSGN a hedge fund favorite?

Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of DSGN, including Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC.

What is DSGN's Smart Money Score?

Our composite Smart Money Score for DSGN is 69 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought DSGN this quarter?
4BAKER BROS. ADVISORS LP2.7M$38.8M+3.6%4.288%0.19%
5DRIEHAUS CAPITAL MANAGEMENT LLC2.7M$38.5M+52.5%4.261%0.22%
6BlackRock, Inc.2.7M$38.5M+24.7%4.259%0.00%
7Caption Management, LLC2.6M$37.9M+2919.4%4.192%0.18%
8Point72 Asset Management, L.P.2.4M$34.2M-13.1%3.789%0.04%
9Trails Edge Capital Partners, LP2.0M$29.0M+134.9%3.204%4.60%
10Frazier Life Sciences Management, L.P.1.8M$26.2M—2.898%0.57%
11Vivo Capital, LLC1.6M$23.3M0.0%2.582%2.13%
12VANGUARD CAPITAL MANAGEMENT LLC1.6M$22.7M+16.4%2.515%0.00%
13Almitas Capital LLC1.0M$14.9M-32.9%1.644%3.56%
14GEODE CAPITAL MANAGEMENT, LLC958K$13.9M+38.4%1.534%0.00%
15Sofinnova Investments, Inc.865K$12.5M—1.385%0.65%
16FMR LLC776K$11.2M-2.8%1.243%0.00%
17MORGAN STANLEY765K$11.1M+16.6%1.226%0.00%
18STATE STREET CORP736K$10.7M+11.6%1.179%0.00%
19Woodline Partners LP700K$10.1M-27.2%1.121%0.03%
20DIMENSIONAL FUND ADVISORS LP695K$10.1M+60.9%1.112%0.00%
21GOLDMAN SACHS GROUP INC657K$9.5M+30.1%1.051%0.00%
22JACOBS LEVY EQUITY MANAGEMENT, INC566K$8.2M+95.5%0.906%0.03%
23Siren, L.L.C.523K$7.6M—0.838%0.15%
24Qube Research & Technologies Ltd437K$6.3M+1178.6%0.700%0.01%
25RENAISSANCE TECHNOLOGIES LLC388K$5.6M-5.0%0.621%0.01%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DSGN — a direct measure of their conviction.

$43.4M
  • BAKER BROS. ADVISORS LP$38.8M
  • DRIEHAUS CAPITAL MANAGEMENT LLC$38.5M
  • BlackRock, Inc.$38.5M
  • Caption Management, LLC$37.9M
  • Point72 Asset Management, L.P.$34.2M
  • Trails Edge Capital Partners, LP$29.0M
  • Vivo Capital, LLC$23.3M
  • VANGUARD CAPITAL MANAGEMENT LLC$22.7M
  • GEODE CAPITAL MANAGEMENT, LLC$13.9M
  • 59.14%
    +1.82 pp
    $126M
    35%
    Q4 2024946.0%57.32%+1.65 pp$195M+19%
    Q3 2024100—55.67%—$164M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    27 institutions opened new positions in DSGN during Q2 2026, while 16 fully exited. 87 added to existing positions and 21 trimmed.

    How is institutional ownership of DSGN changing?

    DSGN institutional ownership rose by 10.84 percentage points quarter-over-quarter, with a net change of +11 holders.

    How concentrated is DSGN ownership among the top holders?

    The top 10 institutions account for 65.4% of all reported 13F value in DSGN, and the top 25 account for 89.1%.

    How does DSGN compare to Rare Disease Biotech on institutional ownership?

    Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this DSGN institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    DSGNDesign Therapeutics, Inc.
    $9.47$591M
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership